Who are Neulasta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rolvedon, Lonquex, Neulasta, Neupogen, Neupogen, FULPHILA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/neulasta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Neulasta — Competitive Intelligence Brief

Neulasta (Neulasta) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Hematology.

marketed Granulocyte colony-stimulating factor receptor Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Neulasta (Neulasta) — Columbia University.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Neulasta TARGET	Neulasta	Columbia University	marketed		Granulocyte colony-stimulating factor receptor
Rolvedon	EFLAPEGRASTIM	Spectrum Pharms	marketed	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor	2022-01-01
Lonquex	LIPEGFILGRASTIM	Sicor Biotech UAB	marketed		Granulocyte colony-stimulating factor receptor	2013-01-01
Neulasta	PEGFILGRASTIM	Amgen	marketed	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor	2002-01-01
Neupogen	Filgrastim-Aafi	Amgen	marketed	Colony-stimulating factor (CSF); leukocyte growth factor	G-CSF receptor (granulocyte colony-stimulating factor receptor)	1991-01-01
Neupogen	Neupogen	University of Chicago	marketed		Granulocyte colony-stimulating factor receptor
FULPHILA	PEGFILGRASTIM-JMDB	MYLAN GMBH	marketed	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neulasta — Competitive Intelligence Brief. https://druglandscape.com/ci/neulasta. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab